| Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares | 09/12 22:34 | globenewswire.com |
| Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares | 09/11 16:04 | globenewswire.com |
| Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | 09/10 07:00 | globenewswire.com |
| Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | 08/27 08:00 | globenewswire.com |
| Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | 08/21 08:00 | globenewswire.com |
| Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 | 08/13 07:00 | globenewswire.com |
| Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade | 07/16 10:56 | zacks.com |
| Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer | 06/10 07:00 | globenewswire.com |
| Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) | 05/28 10:36 | zacks.com |
| Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | 05/21 08:45 | globenewswire.com |